Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
Plain-language summary
This trial is testing allogeneic stem cell transplant (from a donor) for patients with anaplastic large cell lymphoma (ALCL) or extranodal NK/T-cell lymphoma who have been newly diagnosed and have not yet received treatment. This is an early Phase 1 trial, which means this is among the first tests of the treatment in patients, focusing on safety and dose. Patients are randomly assigned to different treatment groups. This trial is available at 6 locations in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 1 Year to 31 Years years
- Newly diagnosed, not yet treated
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Methotrexate (DRUG): Patients will receive methotrexate as part of chemoimmunotherapy regemin followed by allogeneic stem cell transplant. | pralatraxate, (DRUG): Patients will receive pralaxtraxate as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant. | Ifosfamide (DRUG): Patients will receive Ifsofamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant. | Dexamethasone (DRUG): Patients will receive dexamethasone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant. | Etoposide (DRUG): Patients will receive etoposide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant. | calaspargase pegol (DRUG): Patients will receive pegaspargase as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant. | cyclophosphamide (DRUG): Patients will receive cyclophosphamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant. | Doxorubicin (DRUG): Patients will receive doxorubicin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant. | Prednisone (DRUG): Patients will receive prednisone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant. | Brentuximab Vedotin (DRUG): Patients will receive brentuximab vedotin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
Methotrexate, pralatraxate,, Ifosfamide, Dexamethasone, Etoposide, calaspargase pegol, cyclophosphamide, Doxorubicin, Prednisone, Brentuximab Vedotin
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details